Novartis expects higher sales and profitability this year, lifted by its broad range of drugs, and minimal disruption to its supply chain from the coronavirus outbreak in China.

Novartis shares have fallen after US regulators said a unit that developed a costly breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it before the treatment was approved.